All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Medicure
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 05, 2020
Details:
The Agreement grants an exclusive right to Medicure to market and sell the Product in the United States of America, Canada and the European Union.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Coenzyme Q10
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Ubiquinol
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2020
Details:
Ubiquinol (the active form of CoQ10) significantly improved FMD in both treated groups compared with the placebo group (Ubiquinol 200 mg/day; Ubiquinol 100 mg/day; placebo).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Everolimus
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ESPRIT BTK
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 03, 2020
Details:
This is the first Investigational Device Exemption (IDE) trial in the U.S. to evaluate a fully resorbable device to treat blocked arteries below the knees, or critical limb ischemia (CLI), in people battling advanced stages of peripheral artery disease (PAD).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): PMC-403
Therapeutic Area: Cardiology/Vascular Diseases Product Name: PMC-403
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: NIH
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 18, 2020
Details:
Under this agreement, Kirk M. Druey, M.D., and colleagues at the NIAID will investigate PMC-403 in preclinical models. PharmAbcine will discuss potential clinical development in collaboration with the NIH as the study progresses.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Autonomic regulation therapy
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Vitaria
Highest Development Status: Undisclosed Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 12, 2020
Details:
LivaNova will present a poster at the European Society of Cardiology (ESC) Congress 2020 on the potential for autonomic regulation therapy (ART) via vagus nerve stimulation to improve long-term cardiovascular function in patients with heart failure.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Sirolimus
Therapeutic Area: Cardiology/Vascular Diseases Product Name: BuMA Suprem
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 08, 2020
Details:
SINOMED completed 1-year follow-up in the PIONEER-III trial evaluating the BuMA Supreme Drug-Eluting Coronary Stent (DES). BuMA Supreme is Sinomed's second-generation DES with eG Coating, biodegradable polymer and sirolimus drug.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ESI human embryonic stem cells
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ESI hESC
Highest Development Status: Undisclosed Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: AgeX Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 16, 2020
Details:
The agreement is a key step in AgeX’s licensing and collaboration strategy to facilitate industry and academic access to its hESC lines, its PureStem® cell derivation and manufacturing platform, and its UniverCyte™ immunotolerance technology.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Immune globulin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Norton Heart & Vascular Institute in Louisvill
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 28, 2020
Details:
Octapharma USA is donating Octagam® 10% and cutaquig® 16.5%, the company’s intravenous immunoglobulin (IVIG) and subcutaneous immunoglobulin (SCIG), for the study. BioMatrix will be donating patient education, including instruction in subcutaneous injection.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): miRNA-125b
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2020
Details:
The micro-RNA was identified as suitable for further development based on favorable pharmacokinetic results as well as pharmacodynamic data at the molecular level.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Antisense oligonucleotide therapies
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Lipigon
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition March 23, 2020
Details:
Under this agreement, Lipigon acquires certain antisense drug candidates, which were developed with Secarna's proprietary LNAplusTM platform, including the corresponding patent portfolio.